Login to Your Account

96% Unpartnered Cancer Drugs Fail

Attrition High for Biotechs Without Partners; Worth It?

By Trista Morrison

Monday, March 5, 2012

A recent analysis from Deloitte Recap LLC showed that, when it comes to advancing a product from Phase I to approval, the odds are significantly better for biotechs who have a big pharma or big biotech partner.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription